Allopurinol; Lesinurad is Used for treating hyperuricemia associated with gout in patients who have not responded to a sufficient dose of allopurinol alone. It was first introduced by Ironwood Pharmaceuticals Inc in its drug Duzallo on Aug 18, 2017.

Allopurinol; Lesinurad Patents

Given below is the list of patents protecting Allopurinol; Lesinurad, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Duzallo	US10183012	Compounds and compositions and methods of use	Nov 26, 2028	Ironwood Pharms Inc
Duzallo	US8003681	2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and methyl ester	Aug 25, 2025	Ironwood Pharms Inc
Duzallo	US8084483	Compounds and compositions and methods of use	Aug 17, 2029	Ironwood Pharms Inc
Duzallo	US8283369	Compounds and compositions and methods of use	Nov 26, 2028	Ironwood Pharms Inc
Duzallo	US8357713	Compounds and compositions and methods of use	Dec 22, 2029	Ironwood Pharms Inc
Duzallo	US8546436	Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof	Feb 29, 2032	Ironwood Pharms Inc
Duzallo	US8546437	Compounds and compositions and methods of use	Apr 29, 2029	Ironwood Pharms Inc
Duzallo	US9216179	Treatment of gout and hyperuricemia	Aug 01, 2031	Ironwood Pharms Inc
Duzallo	US9956205	Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof	Dec 28, 2031	Ironwood Pharms Inc

Add above patents to watchlist

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳